Literature DB >> 19514917

A comparison of rat chronic progressive nephropathy with human renal disease-implications for human risk assessment.

Gordon C Hard1, Kent J Johnson, Samuel M Cohen.   

Abstract

Chronic progressive nephropathy (CPN) is a single renal disease of unknown etiology, occurring in high incidence in laboratory rats, that can confound subchronic and carcinogenicity bioassay interpretation. It has effects on longevity and, in its early stages, it has a histological similarity to tubular degeneration from other causes. In its advanced stages it is associated with marginally increased renal tubule tumor incidences. Several natural or physiological factors influence its incidence and severity, most prominently protein and caloric intake and male sex hormones. By contrast, there is no entity in humans that presents with the combination or pattern of histological features found in rat CPN. Humans are affected by several different nephropathies of known etiology but generally these are found much less frequently than CPN is found in the rat. There are major differences in pathology between CPN and human nephropathies. Histological characteristics in CPN include prominently dilated tubules filled with proteinaceous casts with consequent kidney enlargement, which contrasts with the shrunken kidneys found in end-stage human nephropathy. Unlike human nephropathy, CPN is devoid of vascular changes, it has no immunological or autoimmune basis, and inflammation is not a prominent feature. Various chemicals exacerbate CPN; no equivalent chemical interactions are seen with human nephropathies. Because some chemicals exacerbate CPN, and advanced CPN is a small risk factor for renal tubule tumor development, an increase in renal tumors can be wrongly attributed to a direct chemical effect on the kidney. On the basis of differences in biology and pathology, this analysis concludes that there is no clear human counterpart of CPN. We recommend that chemically induced exacerbation of CPN not be acknowledged as an indicator of human toxic hazard. Increases in the incidence of CPN-related renal tumor is not considered relevant to humans.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19514917     DOI: 10.1080/10408440802368642

Source DB:  PubMed          Journal:  Crit Rev Toxicol        ISSN: 1040-8444            Impact factor:   5.635


  10 in total

1.  Preclinical Safety Assessment of Therapeutic Oligonucleotides.

Authors:  Patrik Andersson
Journal:  Methods Mol Biol       Date:  2022

Review 2.  Podocyte Aging: Why and How Getting Old Matters.

Authors:  Stuart J Shankland; Yuliang Wang; Andrey S Shaw; Joshua C Vaughan; Jeffrey W Pippin; Oliver Wessely
Journal:  J Am Soc Nephrol       Date:  2021-11       Impact factor: 10.121

3.  Gender differences in chemical carcinogenesis in National Toxicology Program 2-year bioassays.

Authors:  Sandeep Kadekar; Shyamal Peddada; Ilona Silins; John E French; Johan Högberg; Ulla Stenius
Journal:  Toxicol Pathol       Date:  2012-05-14       Impact factor: 1.902

4.  Methionine restriction delays aging-related urogenital diseases in male Fischer 344 rats.

Authors:  Despina Komninou; Virginia L Malloy; Jay A Zimmerman; Raghu Sinha; John P Richie
Journal:  Geroscience       Date:  2019-11-14       Impact factor: 7.713

5.  Physiologically based pharmacokinetic model for ethyl tertiary-butyl ether and tertiary-butyl alcohol in rats: Contribution of binding to α2u-globulin in male rats and high-exposure nonlinear kinetics to toxicity and cancer outcomes.

Authors:  Susan J Borghoff; Caroline Ring; Marcy I Banton; Teresa L Leavens
Journal:  J Appl Toxicol       Date:  2016-11-24       Impact factor: 3.446

Review 6.  Confounders for kidney carcinogenesis in rodent cancer bioassays.

Authors:  Gordon C Hard
Journal:  J Toxicol Pathol       Date:  2021-10-14       Impact factor: 1.628

7.  Mice lacking the mitochondrial exonuclease MGME1 develop inflammatory kidney disease with glomerular dysfunction.

Authors:  Dusanka Milenkovic; Adrián Sanz-Moreno; Julia Calzada-Wack; Birgit Rathkolb; Oana Veronica Amarie; Raffaele Gerlini; Antonio Aguilar-Pimentel; Jelena Misic; Marie-Lune Simard; Eckhard Wolf; Helmut Fuchs; Valerie Gailus-Durner; Martin Hrabě de Angelis; Nils-Göran Larsson
Journal:  PLoS Genet       Date:  2022-05-09       Impact factor: 6.020

8.  Trimethylamine, a gut bacteria metabolite and air pollutant, increases blood pressure and markers of kidney damage including proteinuria and KIM-1 in rats.

Authors:  Klaudia M Maksymiuk; Mateusz Szudzik; Marta Gawryś-Kopczyńska; Maksymilian Onyszkiewicz; Emilia Samborowska; Izabella Mogilnicka; Marcin Ufnal
Journal:  J Transl Med       Date:  2022-10-15       Impact factor: 8.440

9.  Consideration of rat chronic progressive nephropathy in regulatory evaluations for carcinogenicity.

Authors:  Gordon C Hard; Marcy I Banton; Robert S Bretzlaff; Wolfgang Dekant; Jefferson R Fowles; Anthony K Mallett; Douglas B McGregor; Kathleen M Roberts; Robert L Sielken; Ciriaco Valdez-Flores; Samuel M Cohen
Journal:  Toxicol Sci       Date:  2012-10-26       Impact factor: 4.849

Review 10.  The use of whole food animal studies in the safety assessment of genetically modified crops: limitations and recommendations.

Authors:  Andrew Bartholomaeus; Wayne Parrott; Genevieve Bondy; Kate Walker
Journal:  Crit Rev Toxicol       Date:  2013-11       Impact factor: 5.635

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.